Le Lézard
Classified in: Health, Business
Subjects: FNC, TRI

Instylla Announces Completion of Series B Financing


BEDFORD, Mass., Oct. 14, 2020 /PRNewswire/ -- Instylla, Inc., a privately held company developing minimally invasive liquid embolic products designed for use in peripheral vascular embolotherapy today announced closure of $25.4 million Series B financing.  Participants in this latest round of financing included the new investors Excelestar Ventures, Catalyst Health Ventures, and Amed Ventures. Existing investors Ascension Ventures, Sparta Group and Incept also participated.  As part of the financing Tasneem Dohadwala and Darshana Zaveri will join the board. These funds are anticipated to see Instylla through several prospective clinical trials, including a pivotal trial in the United States, in preparation for market entry.

Interventional Radiologists typically use microspheres and metal coils to embolize or occlude blood flow in vessels to treat hypervascular tumors or to control hemorrhage.  Neither of these technologies effectively stop blood flow by themselves but rely on the formation of blood clot around these devices to stop flow. The Instylla lead product, Hydrogel Embolic System (HEStm), is a water-based liquid that when injected into vessels via standard catheters, effectively fills the target vessels and solidifies into a soft, occlusive hydrogel embolic. This results in immediate and persistent flow stasis.  The hydrogel embolic is designed to be absorbable. Currently, there are no liquid embolics approved in the United States for use in the peripheral vasculature, and no absorbable liquid embolics commercially available.

Instylla HES comes from a long line of medical devices based on polyethylene glycol hydrogel which are used as neurosurgical and ocular sealants, femoral puncture closure devices, and organ spacers for radiotherapy. "The water-based chemistry of Instylla HES eliminates concerns related to catheter gluing or compatibility issues which can occur with glues and organic solvent based embolics. The HES is designed to achieve rapid, deep and complete embolization, and I look forward to following its clinical development," said Suvranu "Shoey" Ganguli, M.D., FSIR, Chief, Interventional Radiology, Boston Medical Center and Boston University School of Medicine.

"These funds will allow us to execute the pivotal clinical trial in the US for the embolization of hypervascular tumors for which we recently received approval to proceed from the FDA, along with additional trials in hemorrhage control. We welcome the support of our new investors and look forward to bringing this technology to interventional radiology community," said Amar Sawhney, CEO Instylla and Managing Director of Incept.

"We at Excelestar, along with our co-investors at Catalyst Health Ventures, are thrilled to partner with the deeply experienced and world-class Instylla team to bring these unique and important medical advances to doctors and patients," said Tasneem Dohadwala, Founding Partner at Excelestar Ventures.

About Instylla
Instylla (http://www.instylla.com) is a privately held company in Bedford, MA focused on developing peripheral liquid embolic products based on its proprietary hydrogel technology to improve patient outcomes, procedure efficiency, and enable new therapies.  The company was founded by Incept LLC in 2017 and is funded by several leading venture capital groups and Instylla principals.

The Instylla HES is not approved for sale in the United States.

SOURCE Instylla Inc


These press releases may also interest you

at 06:08
ConTemporary Locums, a physician-focused medical staffing company, is ushering in a new era with a bold rebrand: Era Locums. This brand evolution marks a commitment to continued innovation and a deeper connection with the company's physician and...

at 06:05
AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, is proud to recognize March 25-31 as National Physicians Week. This week and throughout the year, we celebrate the dedication of physicians who selflessly...

at 06:00
The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product With Price and Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2023-2027" report has been added to  ResearchAndMarkets.com's...

at 05:45
The "Global Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product, and Place, with Executive & Consultant Guides; Including Customized Forecasting and Analysis" report has been added to  ResearchAndMarkets.com's offering....

at 05:45
The Gross Law Firm issues the following notice to shareholders of InMode Ltd. . Shareholders who purchased shares of INMD during the...

at 05:30
The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to...



News published on and distributed by: